SCHEMBL5722009

SCHEMBL5722009

O=C(CN1[CH]N(CC(=O)c2cccc(F)c2)C=C1)c1cccc(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.52
CES1 P23141 2/20 0.52
PARP1 P09874 1/20 0.49
MAPT P10636 4/20 0.48
KDM4E B2RXH2 3/20 0.48
HPGD P15428 3/20 0.48
HTT P42858 3/20 0.48
MEN1 O00255 2/20 0.48
NPC1 O15118 2/20 0.48
LMNA P02545 2/20 0.48
TSHR P16473 2/20 0.48
KMT2A Q03164 2/20 0.48
ALOX12 P18054 1/20 0.48
GRIN2B Q13224 2/20 0.47
HDAC1 Q13547 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
PLA2G7 Q13093 1/20 0.45
CTNNB1 P35222 3/20 0.44
WNT3A P56704 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6401174 0.95 GRIN2B (0.50) CES2CES1PARP1MAPTKDM4E
SCHEMBL6399971 0.91 HTT (0.46) CES2CES1PARP1MAPTKDM4E
SCHEMBL6404557 0.89 MGAM (0.43) CES2CES1MAPTKDM4EHPGD
SCHEMBL6399172 0.88 RAB9A (0.58) CES2CES1PARP1MAPTKDM4E
SCHEMBL6404897 0.79 ERCC5 (0.46) CES2CES1PARP1KDM4EMEN1
SCHEMBL5722012 0.79 GRIN2B (0.52) CES2CES1PARP1MAPTKDM4E
SCHEMBL29987428 0.76 MEN1 (0.72) CES2CES1PARP1MAPTKDM4E
SCHEMBL6401176 0.75 GRIN2B (0.55) CES2CES1PARP1MAPTKDM4E
SCHEMBL29772245 0.74 CES2 (0.63) CES2CES1PARP1MAPTKDM4E
SCHEMBL364308 0.74 CES2 (0.63) CES2CES1PARP1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1554253-A4 IMIDAZOLIUM CXCR3 INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-09-20 EP disclosed
US-20050272936-A1 Imidazolium cxcr3 inhibitors SMITHKLINE BEECHAM CORPORATION 2005-12-08 US disclosed
EP-1554253-A1 IMIDAZOLIUM CXCR3 INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-20 EP disclosed
WO-2003101970-A1 IMIDAZOLIUM CXCR3 INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272936-A1 Imidazolium cxcr3 inhibitors CXCR3, CXCR1, CCR7 CES2 1287/4885CES1 948/4885PARP1 1282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.